To be clear... This isn't another China deal... The old deal may have been a China deal but this one is a deal with a consortium of Chinese companies (BYIC) with which we have a contract (see SEC reporting over the past year and a half). This deal includes a CCP FDA review of our vaccine which is what I was referring to.

There has been revenue from BYIC in the amount of $5.1M (see 8Ks from earlier this year).

CCP FDA approval would get the ball rolling on the $50M in revenue from BYIC.

These are facts based on the contract with BYIC.